Bausch & Lomb vs Steris
Steris is the larger business, with $5.94bn of revenue in fiscal 2026 against $5.10bn for Bausch & Lomb (1.2 times as much). Steris grew faster (8.7% against 6.5%). Steris kept more of each dollar of sales as profit: a net margin of 13.2% against -7.1%. Steris carries less debt relative to equity (26.9% against 79.2%).
| Latest fiscal year | Bausch & LombBLCO, 2025 | SterisSTE, 2026 |
|---|---|---|
| Revenue | $5.10bn | $5.94bn |
| Revenue growth | 6.5% | 8.7% |
| Net income | −$360m | $782m |
| Operating margin | 2.2% | 18.6% |
| Net margin | -7.1% | 13.2% |
| Return on equity | -5.6% | 11.3% |
| Free cash flow | −$66.0m | $972m |
| Cash | $383m | $440m |
| Total debt | $5.11bn | $1.93bn |
| Debt to equity | 79.2% | 26.9% |
| Dividend per share | — | $2.46 |
| Dividend yield | — | 1.1% |
| Share buybacks | — | $236m |
| Employees | — | 16,000 |
| Market value | $7.14bn | $22.58bn |
| Price vs our value range | — | Within our value range |
| Moat score | 19 (Weak) | 70 (Moderate) |
| Insider trades, 12 months | 9 buys, 4 sales | 0 buys, 12 sales |